Selective COX-2 inhibitors and risk of myocardial infarction (Q36173750)

12 August 2017

1 reference

title

Selective COX-2 inhibitors and risk of myocardial infarction (English)

1 reference

12 August 2017

Florian Krotz

1

1 reference

12 August 2017

Thomas M Schiele

series ordinal

2

1 reference

12 August 2017

Volker Klauss

series ordinal

3

1 reference

12 August 2017

Hae-Young Sohn

series ordinal

4

1 reference

12 August 2017

language of work or name

1 reference

20 June 2005

1 reference

Journal of Vascular Research

12 August 2017

1 reference

12 August 2017

42

1 reference

12 August 2017

312-324

1 reference

12 August 2017

4

1 reference

Failing the public health--rofecoxib, Merck, and the FDA.

12 August 2017

1 reference

Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs

21 January 2018

1 reference

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic

21 January 2018

1 reference

COX-2 and beyond: Approaches to prostaglandin inhibition in human disease

21 January 2018

1 reference

Cyclooxygenases: structural, cellular, and molecular biology

21 January 2018

1 reference

COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression

21 January 2018

1 reference

COX-3: just another COX or the solitary elusive target of paracetamol?

21 January 2018

1 reference

Prostaglandin synthases: recent developments and a novel hypothesis.

21 January 2018

1 reference

Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists

21 January 2018

1 reference

Platelet prostanoid receptors

21 January 2018

1 reference

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

21 January 2018

1 reference

Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs

21 January 2018

1 reference

Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects

21 January 2018

1 reference

Cyclooxygenase-2 expression in lipopolysaccharide-stimulated human monocytes is modulated by cyclic AMP, prostaglandin E(2), and nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

Cyclooxygenase-2--10 years later

21 January 2018

1 reference

Constitutive expression and localization of COX-1 and COX-2 in rabbit iris and ciliary body.

21 January 2018

1 reference

Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight

21 January 2018

1 reference

Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphavbeta3.

21 January 2018

1 reference

Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells.

21 January 2018

1 reference

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

Parsing an enigma: the pharmacodynamics of aspirin resistance

21 January 2018

1 reference

The COX-2 Selective Inhibitor, Valdecoxib, Does Not Impair Platelet Function in the Elderly: Results of a Randomized Controlled Trial

21 January 2018

1 reference

Valdecoxib does not impair platelet function

21 January 2018

1 reference

The second generation of COX-2 inhibitors: clinical pharmacological point of view

21 January 2018

1 reference

Clinical implications of drug interactions with coxibs

21 January 2018

1 reference

Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids

21 January 2018

1 reference

EDHF, but not NO or prostaglandins, is critical to evoke a conducted dilation upon ACh in hamster arterioles

21 January 2018

1 reference

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 January 2018

1 reference

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

21 January 2018

1 reference

The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

21 January 2018

1 reference

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

21 January 2018

1 reference

Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo

21 January 2018

1 reference

Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor

21 January 2018

1 reference

Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis

21 January 2018

1 reference

Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension

21 January 2018

1 reference

Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2.

21 January 2018

1 reference

Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice

21 January 2018

1 reference

Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing

21 January 2018

1 reference

Selective COX-2 inhibition improves endothelial function in coronary artery disease

21 January 2018

1 reference

Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study

21 January 2018

1 reference

Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease

21 January 2018

1 reference

Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis

21 January 2018

1 reference

Effect of estrogen on cerebrovascular prostaglandins is amplified in mice with dysfunctional NOS.

21 January 2018

1 reference

COX-2-derived prostacyclin confers atheroprotection on female mice

21 January 2018

1 reference

Sexual dimorphism in renal production of prostanoids in spontaneously hypertensive rats

21 January 2018

1 reference

Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population

21 January 2018

1 reference

Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly

21 January 2018

1 reference

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

21 January 2018

1 reference

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

21 January 2018

1 reference

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

21 January 2018

1 reference

Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery

21 January 2018

1 reference

Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis

21 January 2018

1 reference

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 January 2018

1 reference

Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial

21 January 2018

1 reference

Disturbance of vision by COX-2 inhibitors

21 January 2018

1 reference

Nephrotoxic potential of selective cyclooxygenase-2 inhibitors

21 January 2018

1 reference

Cyclooxygenase-2 and inflammation in atherosclerosis

21 January 2018

1 reference

Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins

21 January 2018

1 reference

The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide

21 January 2018

1 reference

Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000086459

1 reference

12 August 2017

1 reference